Incorporated in 2005 and headquartered in Allendale, New Jersey, Amorcyte, Inc. is a development stage cellular therapies company focused on developing novel treatments for cardiovascular disease. Currently, the company is developing its first product, AMR–001, which is a bone marrow-derived, CD34 positive selected stem cell product candidate for the treatment of damaged heart muscle following Acute Myocardial Infarction (AMI). The company completed a Phase I clinical trial which raised no safety concerns and established a biological threshold dose with statistical significance in patients who experienced a STEMI (heart attack). Specifically, at doses ≥10 million CD34+ cells demonstrating SDF-1 mobility, there was a significant improvement in infarct region perfusion, trend to improvement in LVEF, and lower incidence of decreased LVEF at 6-month follow-up compared with patients in the control group and those receiving 5 million cells.

Amorcyte was spun off from Progenitor Cell Therapy (PCT) in 2006 and, in October 2011 was acquired by NeoStem as a wholly-owned company, effectively reuniting it with PCT and providing capital to fund the next steps for its clinical development programs.